{"disease":{"id":"uterine-endometrial-cancer","name":"uterine endometrial cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07382583","title":"Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01705288","title":"Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT05529303","title":"Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Kevser Pamuk","has_results":false},{"nct_id":"NCT06795009","title":"Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT00508703","title":"Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04080284","title":"Trial of Maintenance With Niraparib- Uterine Serous Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT02725489","title":"Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Mary Crowley Medical Research Center","has_results":false},{"nct_id":"NCT04906382","title":"Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Floor Backes, MD","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}